Greenwich Lifesciences Inc (GLSI)

Healthcare Biotechnology

13.50 $

-3.7% vs. previous close

Closing price · As of: 31. Jul 2026

Add to watchlist

Stock Watch

Stock Watch will tell you what changes at Greenwich Lifesciences Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Risk & Weakness

Insolvency Radar: Cash Running Low

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close

14.00$

Open

14.20$

Day High

14.30$

Day Low

13.20$

Volume

85,124shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High

7.90 $ 33.60 $

11/24/2025 01/27/2026

Current price 13.50 $ — 22% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap

0.2$B

Shares Outstanding

15Mio.

Float

50.3%

Beta

1.4

Performance

Perf. 1M

-19.80%

Perf. 3M

4.10%

Perf. 6M

35.10%

YTD Performance (%)

9.60%

52-Week-High Distance

-46.3%

Perf. 1Y

23.40%

Perf. 3Y

46.74%

Perf. 5Y

-65.80%

Perf. Since Inception

170.00%

Technical Indicators

MA 38 Days

19.30$

MA 50 Days

21.00$

MA 200 Days

20.20$

RSI (14)

34.4

Volatility 30 Days

114.8%

Volatility 250 Days

97.9%

Calculated from the price history · as of 08/03/2026

Valuation

P/E

–

Forward P/E

0.0

PEG

–

P/B

40.6

P/S

–

EV/EBITDA

-21.2

Price/FCF

–

Profitability

Gross Margin

–

EBIT Margin

–

Net Margin

0.0%

Return on Equity

-676.7%

Return on Assets

-211.3%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

–

warning zone

Altman Z″

-19.09

Piotroski

5 out of 9

Growth

Sales Growth Last Quarter

0.00%

EPS Growth Last Quarter

0.00%

Sales Growth (Year)

–

Forward Sales Growth

–

Forward EPS Growth

–

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage

RS Rating

EPS Rating

Piotroski

5 out of 9

Fundamental Rating

E (22 out of 100)

warning zone

Altman Z″

-19.09

AI Rating

Neutral

Geprüft am 13.07.2026 gegen den Geschäftsbericht (10-K) für 2025 (eingereicht 01.06.2026) und die vier jüngsten Quartalsberichte (10-Q, zuletzt zum 31.03.2026, eingereicht 04.06.2026). In den ausgewerteten SEC-Filings von Greenwich LifeSciences findet sich kein wesentlicher KI-Bezug: keine Erwähnung von „artificial intelligence“, „machine learning“, „generative“ oder „large language model“ als Produkt, Werkzeug oder Geschäftsrisiko. Die scheinbaren Volltext-Treffer sind ausschließlich falsch-positive Substrings in medizinischen Fachbegriffen („HIV/AIDS“, „neurodegenerative“). Greenwich ist ein klinisches Biopharma-Unternehmen, dessen gesamter Bericht sich um die peptidbasierte Brustkrebs-Immuntherapie GLSI-100 (GP2 + GM-CSF) und die Phase-3-Studie Flamingo-01 dreht — KI spielt weder als Umsatzquelle noch im operativen Betrieb noch als eigenständiges Geschäftsrisiko eine Rolle. Nach dem Kriterienkatalog bleibt es damit bei „neutral“ (dokumentierter Negativ-Befund).

View the full file — quotes, sources, reviewed filings

Filings Reviewed: 10-Q 2026-06-04 · 10-Q 2025-11-14 · 10-Q 2025-08-14 · 10-Q 2025-05-20 · 10-K 2026-06-01 · 10-K 2025-04-15

Rated on July 13, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 13.50 $

Price Target (average) 47.50 $

The price target sits 251.9% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

13. Aug 2026 · after the close · Q2 2026

Expected Earnings per Share: -0.33 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

From To Indexed

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	-0.55	–	–	–	-2	-2
2025: Q1	-0.19	–	-20.00	-68,625.00	-2	-2
2025: Q2	-0.27	–	–	–	-2	-2
2025: Q3	-0.28	–	–	–	-3	-3
2025: Q4	-0.54	–	–	–	-3	-3
2026: Q1	-0.39	–	0.00	-141,425.00	-5	-5

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Greenwich LifeSciences, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt neuartige Krebsimmuntherapien gegen Brustkrebs und andere HER2/neu-exprimierende Krebsarten in den USA.

Employees	4
Headquarters	Stafford, TX
Website	greenwichlifesciences.com
IPO Date	25. Sep 2020

Management

Management
Name	Title	Birth Year
Snehal S. Patel	CEO, CFO & Director	1964
Eric Rothe	Founder & Independent Director	1975
Frank Joseph Daugherty M.D.	Chief Medical Officer & Director	1951
Jaye L. Thompson Ph.D.	Vice President Clinical & Regulatory Affairs	1966
Christine T. Fischette Ph.D.	VP of Business Development	1951

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date	Person	Role	Type	Shares	Price	Value
29. Jul 2026	Patel Snehal	CEO and CFO	Buy	700	13.10	9,170
28. Jul 2026	Patel Snehal	CEO and CFO	Buy	1,500	13.59	20,385
27. Jul 2026	Patel Snehal	CEO and CFO	Buy	1,500	13.62	20,430
24. Jul 2026	Patel Snehal	CEO and CFO	Buy	1,100	12.88	14,168
23. Jul 2026	Patel Snehal	CEO and CFO	Buy	2,500	13.14	32,850

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.